| Business Summary | | Aradigm
Corporation
is
a
developer
of
advanced
pulmonary
drug
delivery
systems
for
the
treatment
of
systemic
conditions
as
well
as
lung
diseases.
The
Company's
hand-held
AERx
platform
is
being
designed
for
the
rapid
and
reproducible
delivery
of
a
wide
range
of
pharmaceutical
drugs
and
biotech
compounds
via
the
lung.
The
Company's
non-invasive
AERx
systems
have
been
shown
in
clinical
studies
to
achieve
performance
equivalent
to
injection-based
delivery
systems.
In
addition,
the
Company's
systems
may
improve
therapeutic
efficacy
in
cases
where
other
existing
drug
delivery
methods,
such
as
pills,
transdermal
patches
or
inhalers,
are
too
slow
or
imprecise. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Aradigm
is
engaged
in
the
development
of
advanced
pulmonary
drug
delivery
systems
for
the
treatment
of
systemic
conditions
as
well
as
lung
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
45%
to
$15.2
million.
Net
loss
before
extraordinary
item
rose
18%
to
$18.6
million.
Results
reflect
revenues
derived
from
collaboration
agreements
with
Novo
Nordisk
A/S
and
GlaxoSmithKline,
offset
by
increased
R
and
D
expenses
related
to
the
development
of
the
AERx
System. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Thompson, 49 Chairman,
Pres, CEO | $407K | Michael Molkentin Acting
CFO, Controller | -- | R. Jerald Beers, 52 Exec.
VP, Marketing and Bus. Devel. | 256K | Norma Milligin, 62 VP,
HR | -- | Bikash Chatterjee, 42 VP,
Pharmaceutical Operations | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|